跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,017 条关于
“PM1080/HS-20117”
全部
1,017
临床试验
579
药物
249
机构
1
资讯
188
11个月前
Roche Acquires Hansoh's CDH17-Targeting ADC HS-20110 in $1.45 Billion Deal
去年
FDA Approves Bimzelx (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa
去年
Secukinumab Demonstrates Improvement in Hidradenitis Suppurativa Symptoms and Psychiatric Comorbidities
2年前
HS-20093 Shows Promise in Pretreated Extensive-Stage Small Cell Lung Cancer
去年
Bimekizumab Shows Promise in Long-Term Management of Hidradenitis Suppurativa
3年前
Acelyrin's Izokibep Fails to Meet Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial
去年
HS-20093 (GSK'227) Receives FDA and EMA Designations for Osteosarcoma and SCLC
2年前
GSK Licenses Hansoh Pharma's B7-H3 ADC, HS-20093, for $185 Million Upfront
去年
FDA Approves Bimekizumab (Bimzelx) for Moderate to Severe Hidradenitis Suppurativa
去年
Non-Small Cell Lung Cancer Clinical Trial Pipeline Sees Significant Growth
第 1 页,共 19 页
上一页
下一页